| Dextromethorphan Hydrobromide and Bupropion Hydrochloride | Axsome Therapeutics | ||
| 45 mg/105 mg; Tablet, Extended release |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
| None | None | ||
| None | None | ||
| AUVELITY is a combination of dextromethorphan, an uncompetitive N-methyl D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist, and bupropion, an aminoketone and CYP450 2D6 inhibitor, indicated for the treatment of major depressive disorder (MDD) in adults | |||
|
Yes
| |||
| Auvelity | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 | Patent 20 | Patent 21 | Patent 22 | Patent 23 | Patent 24 | Patent 25 | Patent 26 | Patent 27 | Patent 28 | Patent 29 | Patent 30 | Patent 31 | Patent 32 | Patent 33 | Patent 34 | Patent 35 | Patent 36 | Patent 37 | Patent 38 | Patent 39 | Patent 40 | Patent 41 | Patent 42 | Patent 43 | Patent 44 | Patent 45 | Patent 46 | Patent 47 | Patent 48 | Patent 49 | Patent 50 | Patent 51 | Patent 52 | Patent 53 | Patent 54 | Patent 55 | Patent 56 | Patent 57 | Patent 58 | Patent 59 | Patent 60 | Patent 61 | Patent 62 | Patent 63 | Patent 64 | Patent 65 | Patent 66 | Patent 67 | Patent 68 | Patent 69 | Patent 70 | Patent 71 | Patent 72 | Patent 73 | Patent 74 | Patent 75 | Patent 76 | Patent 77 | Patent 78 | Patent 79 | Patent 80 | Patent 81 | Patent 82 | Patent 83 | Patent 84 | Patent 85 | Patent 86 | Patent 87 | Patent 88 | Patent 89 | Patent 90 | Patent 91 | Patent 92 | Patent 93 | Patent 94 | Patent 95 | Patent 96 | Patent 97 | Patent 98 | Patent 99 | Patent 100 | Patent 101 | Patent 102 | Patent 103 | Patent 104 | Patent 105 | Patent 106 | Patent 107 | Patent 108 | Patent 109 | Patent 110 | Patent 111 | Patent 112 | Patent 113 | Patent 114 | Patent 115 | Patent 116 | Patent 117 | Patent 118 | Patent 119 | Patent 120 | Patent 121 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **** | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | **** ** *** **, **** | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | **** ** *** **, **** | *** ********* | **** ** *** **, **** | *** ********* | *** ********* | **** ** *** **, **** | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | *** ********* (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | *** ********* (***** ******) | **** ** **** **, **** (***** ******) | **** ** **** **, **** (***** ******) | **** ** **** **, **** (***** ******) | *** ********* (***** ******) | **** ** *** **, **** (***** ******) |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| **** | *** \ ********* | *** **, **** | ******* | **** | *** ****** *** **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|